Israel Biotech Fund I, L.P. 3
3 · Ayala Pharmaceuticals, Inc. · Filed May 7, 2020
Insider Transaction Report
Form 3
Israel Biotech Fund I, L.P.
10% Owner
Holdings
Series B Preferred Stock
→ Common Stock (211,757 underlying)- 2,509,131
Common Stock
Series A Preferred Stock
→ Common Stock (369,231 underlying)
Footnotes (1)
- [F1]The preferred stock is convertible at any time, at the holder's election and has no expiration date. Each share of preferred stock shall be automatically converted into one (1) share of common stock upon the closing of the Issuer's initial public offering.